Infectious Diseases Ward I

The Department of Infectious Diseases of the Second Affiliated Hospital of Harbin Medical University is a comprehensive clinical department with a long history and integrated development in medical care, teaching, and research. Established in 1962, after more than 60 years it has become a well-known infectious-disease discipline among China’s higher medical schools. It has played important roles in major public-safety events, is qualified as a national clinical trial institution for infectious diseases, and has participated in numerous clinical trials. With the joint efforts of all staff, it is moving toward becoming a university- and provincial-level key discipline.

Annual outpatient visits reached 18,975 in 2018, and annual admissions exceeded 3,000. More than 20 disease types are treated; over 50% are various viral hepatitis types, cirrhosis, and severe liver disease, with significant treatment results. The department is one of the few in Heilongjiang able to perform YMDD mutation testing and HCV genotyping, which provides important guidance for clinical treatment of hepatitis B and C. It also has extensive clinical experience in hemorrhagic fever with renal syndrome, brucellosis, liver fluke disease, infectious diarrhea, and fever of unknown origin. Patients with toxic bacillary dysentery can achieve a 100% cure rate.

The department has 2 wards and 170 beds. There are 41 medical and nursing staff: 20 doctors divided into 2 medical units, and 26 nurses divided into 2 nursing units. Among the medical staff, 3 hold doctoral degrees and 13 hold master’s degrees; 3 doctors are currently pursuing doctorates.

The medical staff have solid theoretical knowledge, extensive clinical experience, and strong research capacity. They have obtained 4 provincial/ministerial, 6 departmental, and 1 municipal research project. The department has published more than 70 papers, including 4 SCI papers and more than 60 papers in core journals such as Chinese Journal of Infectious Diseases, Chinese Journal of Nosocomiology, Chinese Journal of Internal Medicine, and Liver. Staff participated in writing Infectious Diseases, Fundamentals and Clinical Practice of Severe Hepatitis, Prevention and Treatment of Common Infectious Diseases in Northern China, and Differential Diagnosis and Treatment of Difficult Diseases in Geriatric Internal Medicine. Research projects have included evaluation of pegylated interferon-2a (Pegasys®) for HBeAg-positive chronic hepatitis B, a phase III study of injectable recombinant human thymosin α1 for chronic hepatitis B, evaluation of telbivudine 600 mg tablets in Chinese patients with chronic hepatitis B, and a phase II study of a therapeutic synthetic-peptide hepatitis B vaccine for chronic hepatitis B.